Upon analysis of the immune mediators of the tumor, we saw significant downregulation of pathological inflammatory signaling of IL-6 and IL-1beta, which are each implicated in breast cancer tumor growth and progression (Figure 4C,D) [40,41]. This evidence concerns the gene IL1B and breast carcinoma.